"Die Evangelische Lungenklinik, ein Unternehmen der Johannesstift Diakonie, ist seit ihrer Gründung im Jahr 1952 eine weithin anerkannte Spezialklinik für akute und chronische Erkrankungen der Lunge sowie des Brustkorbs. Die in Berlin-Buch gelegene Klinik behandelt rund 6.400 stationäre und etwa 12.200 ambulante Patienten jährlich und ist Akademisches Lehrkrankenhaus der Charité – Universitätsmedizin Berlin."

During the past decade, Evangelische Lungenklinik Berlin conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 14 clinical trials were completed, i.e. on average, 41.2% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 7 clinical trials were completed. i.e. 41.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Evangelische Lungenklinik Berlin" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Clovis Oncology, Inc." with 2 trials sponsored and "AIO-Studien-gGmbH" with 2 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Evangelische Lungenklinik Berlin" #1 collaborator was "Bristol-Myers Squibb" with 3 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "German Research Foundation" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Evangelische Lungenklinik Berlin" are "Carcinoma, Non-Small-Cell Lung" (7 trials), "Idiopathic Pulmonary Fibrosis" (7 trials), "Non-Small Cell Lung Cancer" (6 trials), "Non-small Cell Lung Cancer" (4 trials) and "Lung Cancer" (2 trials). Many other conditions were trialed in "Evangelische Lungenklinik Berlin" in a lesser frequency.

Most popular intervention types in "Evangelische Lungenklinik Berlin" are "Drug" (39 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Carboplatin" (6 trials), "Pemetrexed" (6 trials), "Docetaxel" (5 trials) and "Amivantamab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Evangelische Lungenklinik Berlin" are 43 trials for "All" genders.

Currently, there are NaN active trials in "Evangelische Lungenklinik Berlin". undefined are not yet recruiting, 11 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 15 completed trials in Evangelische Lungenklinik Berlin, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Evangelische Lungenklinik Berlin, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".